190 related articles for article (PubMed ID: 30176211)
1. [De-sensitization to allopurinol in a patient with tophi gout].
López-Rocha EG; Hernández-Montoya G; Rodríguez-Pesina AH; Rodríguez-Mireles KA
Rev Alerg Mex; 2018; 65(3):316-320. PubMed ID: 30176211
[TBL] [Abstract][Full Text] [Related]
2. Allopurinol and Loss of Consciousness in a 78-old Year Man Suffering from Gout.
Arian M; AkbariRad M; Moghaddam AB; Firoozi A; Jami M
Infect Disord Drug Targets; 2020; 20(2):253-256. PubMed ID: 30686265
[TBL] [Abstract][Full Text] [Related]
3. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity.
Gillott TJ; Whallett A; Zaphiropoulos G
Rheumatology (Oxford); 1999 Jan; 38(1):85-6. PubMed ID: 10334688
[No Abstract] [Full Text] [Related]
4. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol-induced DRESS syndrome.
Markel A
Isr Med Assoc J; 2005 Oct; 7(10):656-60. PubMed ID: 16259349
[TBL] [Abstract][Full Text] [Related]
6. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
7. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient.
Fam AG
Curr Rheumatol Rep; 2001 Feb; 3(1):29-35. PubMed ID: 11177768
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Chohan S
J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
[TBL] [Abstract][Full Text] [Related]
9. [Fatal outcome in allopurinol hypersensitivity syndrome].
Kluger E
Ugeskr Laeger; 1998 Feb; 160(8):1179-80. PubMed ID: 9492630
[TBL] [Abstract][Full Text] [Related]
10. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
11. Desensitization to allopurinol in a patient with previous failed desensitization.
Tanna SB; Barnes JF; Seth SK
Ann Pharmacother; 1999 Nov; 33(11):1180-3. PubMed ID: 10573316
[TBL] [Abstract][Full Text] [Related]
12. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules.
Calogiuri G; Nettis E; Di Leo E; Foti C; Ferrannini A; Butani L
Inflamm Allergy Drug Targets; 2013 Feb; 12(1):19-28. PubMed ID: 23092365
[TBL] [Abstract][Full Text] [Related]
15. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.
Ramasamy SN; Korb-Wells CS; Kannangara DR; Smith MW; Wang N; Roberts DM; Graham GG; Williams KM; Day RO
Drug Saf; 2013 Oct; 36(10):953-80. PubMed ID: 23873481
[TBL] [Abstract][Full Text] [Related]
16. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.
Gutiérrez-Macías A; Lizarralde-Palacios E; Martínez-Odriozola P; Miguel-De la Villa F
BMJ; 2005 Sep; 331(7517):623-4. PubMed ID: 16166134
[No Abstract] [Full Text] [Related]
17. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
18. Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia.
JAMA; 2018 Jan; 319(2):188-189. PubMed ID: 29318274
[No Abstract] [Full Text] [Related]
19. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
20. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
[No Abstract] [Full Text] [Related]
[Next] [New Search]
